Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers

키워드

참고문헌 (66)

1. Global Burden of Disease Liver Cancer Collaboration, "The burden of primary liver cancer and underlying etiologies from 1990 to 2015at the global, regional, and national level : results from the global burden of disease study 2015", JAMA Oncol, 3, pp.1683~1691 (2017)
2. European Association for the Study of the Liver, "EASL clinical practice guidelines : management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
3. Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 practice guidance by the American Association for the Study of Liver Diseases", Hepatology, 68, pp.723~750 (2018)
4. Joo I, "Recent advances in the imaging diagnosis of hepatocellular carcinoma : value of gadoxetic acid-enhanced MRI", Liver Cancer, 5, pp.67~87 (2016)
5. Choi JY, "CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. extracellular agents, hepatobiliary agents, and ancillary imaging features", Radiology, 273, pp.30~50 (2014)
6. Park YS, "Differentiation of hepatocellular carcinoma from its various mimickers in liver magnetic resonance imaging : what are the tips when using hepatocyte-specific agents", World J Gastroenterol, 22, pp.284~299 (2016)
7. Hope TA, "Hepatobiliary agents and their role in LI-RADS", Abdom Imaging, 40, pp.613~625 (2015)
8. Omata M, "Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma : a 2017 update", Hepatol Int, 11, pp.317~370 (2017)
9. Kudo M, "General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines : the outstanding achievements of the liver cancer study group of Japan", Dig Dis, 33, pp.765~770 (2015)
10. 한국 간 암 스터디그룹, "2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma", Gut and Liver, 9(3), pp.267~317 (2015), 거트앤리버 소화기연관학회협의회
11. Mitchell DG, "LI-RADS(Liver Imaging Reporting and Data System) : summary, discussion, and consensus of the LI-RADS Management Working Group and future directions", Hepatology, 61, pp.1056~1065 (2015)
12. Renzulli M, "New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis : a new diagnostic algorithm", Gut, 67, pp.1674~1682 (2018)
13. Choi SH, "Diagnostic criteria for hepatocellular carcinoma <", =3 cm with hepatocytespecific contrast-enhanced magnetic resonance imaging, 2016, pp.64, 1099~1107
14. Joo I, "Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI : can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features", Eur Radiol, 29, pp.1724~1732 (2019)
15. Kim YY, "Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System(LI-RADS)in gadoxetate-enhanced MRI", Eur Radiol, 28, pp.2038~2046 (2018)
16. Choi SH, "Liver Imaging Reporting and Data System v2014 with gadoxetate disodiumenhanced magnetic resonance imaging : validation of LI-RADS category 4 and 5 criteria", Invest Radiol, 51, pp.483~490 (2016)
17. Kierans AS, "The diagnostic performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm : a meta-analysis", Radiology, 278, pp.82~94 (2016)
18. Chen L, "Comparison of MRI with liver-specific contrast agents and multidetector row CT for the detection of hepatocellular carcinoma : a meta-analysis of 15direct comparative studies", Gut, 62, pp.1520~1521 (2013)
19. Wu LM, "Is liver-specific gadoxetic acid-enhanced magnetic resonance imaging a reliable tool for detection of hepatocellular carcinoma in patients with chronic liver disease", Dig Dis Sci, 58, pp.3313~3325 (2013)
20. Park MJ, "Small hepatocellular carcinomas : improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns", Radiology, 264, pp.761~770 (2012)
21. Kim HD, "Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival", Gastroenterology, 148, pp.1371~1382 (2015)
22. Kim BR, "Diagnostic performance of gadoxetic acid-enhanced liver MR imaging versus multidetector CT in the detection of dysplastic nodules and early hepatocellular carcinoma", Radiology, 285, pp.134~146 (2017)
23. Park YN, "Update on precursor and early lesions of hepatocellular carcinomas", Arch Pathol Lab Med, 135, pp.704~715 (2011)
24. Choi JY, "CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects", Radiology, 272, pp.635~654 (2014)
25. Ueno A, "OATP1B3 expression is strongly associated with Wnt", β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma, 2014, pp.61, 1080~1087
26. Yoneda N, "Benign hepatocellular nodules : hepatobiliary phase of gadoxetic acid-enhanced MR imaging based on molecular background", Radiographics, 36, pp.2010~2027 (2016)
27. Kitao A, "The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis : correlation with gadoxetic acid enhanced MR imaging", Eur Radiol, 21, pp.2056~2066 (2011)
28. Suh CH, "Hypervascular transformation of hypovascular hypointense nodules in the hepatobiliary phase of gadoxetic acid-enhanced MRI : a systematic review and meta-analysis", AJR Am J Roentgenol, 209, pp.781~789 (2017)
29. Toyoda H, "Nonhypervascular hypointense nodules detected by Gd-EOB-DTPAenhanced MRI are a risk factor for recurrence of HCC after hepatectomy", J Hepatol, 58, pp.1174~1180 (2013)
30. Lee DH, "Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MRI : risk of HCC recurrence after radiofrequency ablation", J Hepatol, 62, pp.1122~1130 (2015)
31. 안지현, "Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology", Korean Journal of Radiology, 18(3), pp.427~443 (2017), 대한영상의학회[DOI]
32. Joo I, "Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI : can hypointensity on the hepatobiliary phase be used as an alternative to washout", Eur Radiol, 25, pp.2859~2868 (2015)
33. Choi SH, "Intrahepatic cholangiocarcinoma in patients with cirrhosis : differentiation from hepatocellular carcinoma by using gadoxetic acid-enhanced MR imaging and dynamic CT", Radiology, 282, pp.771~781 (2017)
34. Kim R, "Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging", Eur Radiol, 26, pp.1808~1817 (2016)
35. "CT/MRI LI-RADS(R) v2018"[URL]
36. Lee DH, "Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines : correlation with histopathologic findings", Radiology, 274, pp.149~160 (2015)
37. Min JH, "Prospective intraindividual comparison of magnetic resonance imaging with gadoxetic acid and extracellular contrast for diagnosis of hepatocellular carcinomas using the Liver Imaging Reporting and Data System", Hepatology, 68, pp.2254~2266 (2018)
38. Chong YS, "Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI", Clin Radiol, 67, pp.766~773 (2012)
39. Joo I, "Diagnostic accuracy of liver imaging reporting and data system(LI-RADS)v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI", J Magn Reson Imaging, 44, pp.1330~1338 (2016)
40. Jeong HT, "Gadoxetate disodium-enhanced MRI of mass-forming intrahepatic cholangiocarcinomas : imaging-histologic correlation", AJR Am J Roentgenol, 201, pp.W603~ (2013)[DOI]
41. Min JH, "Differentiation between cholangiocarcinoma and hepatocellular carcinoma with target sign on diffusion-weighted imaging and hepatobiliary phase gadoxetic acid-enhanced MR imaging : classification tree analysis applying capsule and septum", Eur J Radiol, 92, pp.1~10 (2017)
42. Hwang J, "Capsule, septum, and T2 hyperintense foci for differentiation between large hepatocellular carcinoma(≥5 cm)and intrahepatic cholangiocarcinoma on gadoxetic acid MRI", Eur Radiol, 27, pp.4581~4590 (2017)
43. Huang B, "Small intrahepatic cholangiocarcinoma and hepatocellular carcinoma in cirrhotic livers may share similar enhancement patterns at multiphase dynamic MR imaging", Radiology, 281, pp.150~157 (2016)
44. Aishima S, "Pathogenesis and classification of intrahepatic cholangiocarcinoma : different characters of perihilar large duct type versus peripheral small duct type", J Hepatobiliary Pancreat Sci, 22, pp.94~100 (2015)
45. Xu J, "Intrahepatic cholangiocarcinomas in cirrhosis are hypervascular in comparison with those in normal livers", Liver Int, 32, pp.1156~1164 (2012)
46. Joo I, "Imaging diagnosis of intrahepatic and perihilar cholangiocarcinoma : recent advances and challenges", Radiology, 288, pp.7~13 (2018)
47. Brunt E, "cHCC-CCA : consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation", Hepatology, 68, pp.113~126 (2018)
48. Hwang J, "Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI", J Magn Reson Imaging, 36, pp.881~889 (2012)
49. Park SH, "Combined hepatocellular-cholangiocarcinoma : gadoxetic acid-enhanced MRI findings correlated with pathologic features and prognosis", J Magn Reson Imaging, 46, pp.267~280 (2017)
50. Jeon SK, "Combined hepatocellular cholangiocarcinoma : LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acidenhanced MR imaging", Eur Radiol, 29, pp.373~382 (2019)
51. Silva AC, "MR imaging of hypervascular liver masses : a review of current techniques", Radiographics, 29, pp.385~402 (2009)
52. Kitao A, "Hepatocellular carcinoma : signal intensity at gadoxetic acid-enhanced MR imaging--correlation with molecular transporters and histopathologic features", Radiology, 256, pp.817~826 (2010)
53. Suh YJ, "Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI", AJR Am J Roentgenol, 197, pp.W44~ (2011)[DOI]
54. Kitao A, "Differentiation between hepatocellular carcinoma showing hyperintensity on the hepatobiliary phase of gadoxetic acid-enhanced MRI and focal nodular hyperplasia by CT and MRI", AJR Am J Roentgenol, 211, pp.347~357 (2018)
55. Nault JC, "Molecular classification of hepatocellular adenoma in clinical practice", J Hepatol, 67, pp.1074~1083 (2017)
56. Ba-Ssalamah A, "Morphologic and molecular features of hepatocellular adenoma with gadoxetic acid-enhanced MR imaging", Radiology, 277, pp.104~113 (2015)
57. Doo KW, ""Pseudo washout"sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor", AJR Am J Roentgenol, 193, pp.W490~ (2009)[DOI]
58. Kim B, "Enhancement patterns and pseudo-washout of hepatic haemangiomas on gadoxetate disodium-enhanced liver MRI", Eur Radiol, 26, pp.191~198 (2016)
59. Guglielmo FF, "Hepatic MR imaging techniques, optimization, and artifacts", Magn Reson Imaging Clin N Am, 22, pp.263~282 (2014)
60. Tamada T, "Hepatic hemangiomas : evaluation of enhancement patterns at dynamic MRI with gadoxetate disodium", AJR Am J Roentgenol, 196, pp.824~830 (2011)
61. Nam SJ, "High-flow haemangiomas versus hypervascular hepatocellular carcinoma showing"pseudowashout"on gadoxetic acid-enhanced hepatic MRI : value of diffusion-weighted imaging in the differential diagnosis of small lesions", Clin Radiol, 72, pp.247~254 (2017)
62. Choi JY, "Indeterminate observations(liver imaging reporting and data system category 3)on MRI in the cirrhotic liver : fate and clinical implications", AJR Am J Roentgenol, 201, pp.993~1001 (2013)
63. Motosugi U, "Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging", Radiology, 256, pp.151~158 (2010)
64. Sun HY, "Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas(< or =2 cm in diameter)from arterial enhancing pseudolesions : special emphasis on hepatobiliary phase imaging", Invest Radiol, 45, pp.96~103 (2010)
65. Lee SJ, "Hepatic angiomyolipoma versus hepatocellular carcinoma in the noncirrhotic liver on gadoxetic acid-enhanced MRI : a diagnostic challenge", AJR Am J Roentgenol, 207, pp.562~570 (2016)
66. Kim R, "Differentiation of lipid poor angiomyolipoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging", Abdom Imaging, 40, pp.531~541 (2015)

관련 논문AI추천